aod9604 wada prohibited list status 2025 World Anti-Doping Agency (WADA) Update WADA just added tirzepatide (mounjaro)

When hormone-sensitive lipase is active, it cleaves the bonds holding triglycerides together, releasing fatty acids into the bloodstream where they can be oxidized for energy

No Impact on IGF-1 or Blood Sugar Levels Unlike full hGH, which can lead to increased IGF-1 and insulin resistance, AOD-9604 does not interfere with glucose metabolism

AOD-9604 has demonstrated an excellent safety profile in clinical trials involving approximately 900 participants

Any medication that affects glucose, lipid metabolism, growth hormone signaling, or beta-adrenergic activity could in theory interact, but evidence is absent

In research, 5-Amino-1MQ is being studied in combination with complementary compounds: caloric restriction (demonstrated synergistic effect on the microbiome), NMN/NR (NAD+ precursors), and physical exercise (sustained performance enhancement)

Developed by Metabolic Pharmaceuticals in Australia, AOD-9604 was engineered to retain the fat-reducing properties of intact growth hormone while eliminating the undesirable effects on glucose metabolism, insulin sensitivity, and tissue growth